

## Pharmacological and biochemical assessment of Talc on Doxorubicin induced cardiac remodelling in albino Wistar rats

Rajbala Singh<sup>1</sup>, Ruqaiyah Khan<sup>1</sup>, Deepak Tiwari<sup>2</sup>, Hemant<sup>2</sup>, Rajbir Singh<sup>3</sup>, Firoz Anwar<sup>4\*</sup>

<sup>1</sup>Sunrise University, Alwar, Rajasthan, India

<sup>2</sup>Siddhartha Institute of Pharmacy, Dehradun, Uttarakhand, India

<sup>3</sup>Alchemist hospitals, Panchkula, Haryana, India

<sup>4</sup>Department of Biochemistry, Faculty of Science, King Abdulaziz University-Jeddah, Kingdom of Saudi Arabia

### ABSTRACT

**Background and Objectives:** Cardiac remodelling may be defined as genome expression, molecular, cellular and interstitial changes that are apparently changes in size, shape and function of the heart after cardiac injury. Type-2 diabetes is associated with significantly higher risk of heart failure (HF), coronary artery disease (CAD) and cardiac remodelling. Present study was aimed as to evaluate the Pharmacological and biochemical effects of Talc in doxorubicin induced cardiac remodelling in Wistar rat. **Method:** Albino Wistar Rats (100-150gm) were divided into 8 groups (n=6), cardiac remodelling were induced Doxorubicin with a 2.0 mg/kg i.p. twice in a week for 20 weeks) and oral dose of talc (0.14mg/kg) for the period of 20 weeks and treated with Paracetamol for 5 day. **Result and Conclusion:** Exposure of Doxorubicin and Talc altered all biochemical parameter as Blood glucose, Triglyceride, CRP and Troponin-T etc. In conclusion, it was clear that talc may promotecardiac remodelling in Wistar rats.

**Keywords:** Blood glucose, Blood glucose, CRP, Troponin-T

### Introduction

Remodelling is defined as alteration in the structure (dimensions, mass, shape) of the heart (called cardiac or ventricular remodelling) in response to hemodynamic load and/or cardiac injury in association with neuro-hormonal activation [1, 2]. The cardiac cells involved in the remodelling process are cardiomyocytes and fibroblasts. Fibroblast stimulation increases collagen synthesis and causes fibrosis of both the infarcted and non- infarcted regions of the ventricle [3]. This leads to a loss of cardiomyocytes by apoptosis or necrosis. Eventually these cardiomyocytes are replaced by fibroblasts and extracellular collagen. Doxorubicin (DOX), an anthracycline has been widely used in the treatment of all forms of cancer but its use is limited due to its toxicity effect especially on the cardiac tissues. The Doxorubicin induced cardiotoxicity has been shown to be mediated

through different mechanisms, including membrane lipid peroxidation, ROS formation and mitochondrion damage [4]. Due to the lack of developed antioxidant defence system, these free radicals produced by electron transfer from the semiquinone to quinone moieties of the anthracycline that are responsible for myocardial damage and subsequent doxorubicin induced cardiotoxicity[5]. Paracetamol (known as acetaminophen in the United States) is one of the most commonly used non-steroidal anti-inflammatory drugs (NSAIDs) [6]. It is a rapid, reversible, non-competitive inhibitor of cyclooxygenase activity (Cox-3) in the brain and spinal cord and thus products of the arachidonic acid cascade; acetaminophen has been available since the 1950s as an over-the-counter product for pain and fever relief. Although its metabolism is quite well understood, the mechanism of acetaminophen toxicity remains somewhat a mystery with recent evidence suggesting that multiple cytotoxic pathways are involved. Paracetamol is a widely used analgesic and antipyretic drug [7]. Talc is defined as hydrous magnesium silicate,  $Mg_3Si_4O_{10}(OH)_2$  consists of a brucite sheet containing magnesium ions pack

\*Correspondence

Dr. Firoz Anwar

Department of Biochemistry, Faculty of Science, King Abdulaziz University-Jeddah, Kingdom of Saudi Arabia

Email: [firoz\\_anwar2000@yahoo.com](mailto:firoz_anwar2000@yahoo.com)

between two silica sheets which are held mutually by relatively weak forces and belongs to the silicate subclass phyllosilicate and the clay group montmorillonite/smectite. Nickel and iron a variety of elements may be included in the talc particle lattice but are so bound within the particle that they are not free to exert any biological action [8]. In the review of pharmaceutical excipients, Golightly et al. (1988) state, "Ingestion of talc is very unlikely to be toxic [9]." Our previous result was based on the pharmacological action of excipient in anticancer drug, have given an influence that Talc may induced Type-2 diabetes [10]; Diabetes accounted for a significant percentage of patients with a diagnosis of heart failure in numerous epidemiologic studies [11]. The United Kingdom Prospective Diabetes Study [12], Cardiovascular Health Study [13], and Euro Heart Failure Surveys [14] all suggested that the presence of diabetes may independently increase the risk of developing incident heart failure; Thus Cardiac remodelling protocol was designed. Albino Wistar male/female rats weighing about 100-150 gm, were procured from Siddhartha institute of pharmacy, Dehradun. The Albino Wistar rats were housed under temperature ( $25 \pm 2^\circ\text{C}$ ) and relative humidity (30-70%) with a 12:12 light-dark cycle, and acclimatized in the animal house facility of the department under ambient condition. The animals were fed with standard semi purified diet and water. All the experiments on animals were conducted in accordance with the internationally accepted principles for laboratory animal use and as per the experimental protocols duly approved by the Institutional Ethical Committee (IAEC No. 1435/PO/a/11/CPCSEA) with the project approval no- "SIP/IAEC/02/2014" by the Institutional Animal Ethical Committee (IAEC) of Siddhartha College of pharmacy, Dehradun. The rats were acclimatized and randomly divided into 08 groups and each group have 6 rats; (1) **Normal control (NC)** - Rats were administered with normal diet and were not given any treatment during the research study. (2) **DOX Control**-Rats of this group were administered Doxorubicin with a 2.0 mg/kg i.p. twice in a week for 20 weeks (3) **Talc control**- Rats of this group were administered with Talc with a 0.14mg/kg oral dose for 20 weeks [10]. (4) **PCM control**- Rats of this group were administered with normal diet for 20 weeks and after that were given PCM (500 mg/kg/d) for 5 days. (5) **DOX +Talc control**- Rats of this group were administered Doxorubicin with a 2.0 mg/kg body weight i.p. twice in a week and also administered Talc with a 0.14mg/kg oral dose for 20 weeks. (6) **DOX +PCM control**- Rats of this group were administered Doxorubicin with a 2.0 mg/kg body weight i.p. twice in a week and were given PCM (500 mg/kg/d) for 5 days.

(7) **Talc+PCM control**- Rats of this group were administered Talc with a 0.14mg/kg oral dose for 20 weeks and were given PCM (500 mg/kg/d) for 5 days.

(8) **DOX+Talc+PCM control**- Rats of this group were administered Doxorubicin with a 2.0 mg/kg body weight i.p. twice in a week and administered Talc with a 0.14mg/kg oral dose for 20 weeks and were given PCM (500 mg/kg/d) for 5 days.

#### **Induction of cardiac remodelling**

Cardiac remodelling was induced by a Doxorubicin dose of 2.0 mg/kg body weight twice in a week.

#### **Determination of biochemical parameters**

##### **Isolation of Serum**

At the end of the treatment period, animals were fasted overnight. Blood sample was collected on termination of the experiment from retro-orbital plexus under light ether anesthesia without any anticoagulant and allowed to stand for 30 minutes at room temperature then centrifuged at 250 rpm for 10 minutes to separate the serum. The serum obtained was kept at  $2^\circ\text{C}$  - $4^\circ\text{C}$  until used.

##### **Blood glucose measurement using Glucometer**

Blood glucose was measured using digital glucometer. Drop of blood was placed on one side of test strip that was inserted in the glucometer. The glucose level was displayed on to the screen within 20 seconds.

##### **C-reactive protein**

The levels of C-reactive protein (CRP) are enhanced by HF. Higher C-reactive protein predicts worse prognosis in acute heart failure only in non infected patients. Recent studies have reported a potential added-value of CRP for the risk prediction of adverse clinical events independently of natriuretic peptides. The potential advantage of CRP testing is its availability within the majority of laboratories through automated assays.

##### **Troponin-T**

Cardiac troponin T (cTnT) was measured on Elec-sys 2010 Immunoassay System (Roche Diagnostics, Indianapolis, IN). The method employs two monoclonal antibodies specifically directed against human cardiac troponin T, with electrochemiluminescent detection. This is a recent, sensitive third-generation assay standardized with human recombinant cTnT, with a limit of detection of 0.01 ng/ml. 0.1 ng/ml is recommended as the clinical threshold value, above which damage to the myocardium can be assumed.

##### **Statistical analysis**

Statistical analysis was carried out using Graph Pad Prism 5.0 (Graph Pad Software, San Diego, CA,

USA). The results were expressed as mean  $\pm$  SEM. Statistical significance between more than two groups was tested using one-way ANOVA followed by Tukey's multiple comparison tests. The *p* values less than 0.001 were considered significant.

## Results

### Blood Glucose

The DOX control were showed not significant (*ns*) effect and Talc control were displayed significantly increased ( $p < 0.001$ ) result of Blood glucose as compared to NC group. On the other hand Talc treated groups displayed significantly elevated level ( $p < 0.001$ ) of blood glucose as compared to DOX Control group; while PCM control were showed not significant (*ns*) level of blood glucose when compare with DOX control group (Table no. 1).

### Triglyceride

The DOX control were displayed not significant (*ns*) effect and Talc control were displayed significantly upward ( $p < 0.001$ ) level of Triglyceride as compared to NC group. On the other hand Talc control and Talc+PCM control were illustrated significantly elevated level ( $p < 0.001$ ) of Triglyceride as compared to DOX Control group; while PCM control and DOX+Talc control were showed not significant (*ns*) level of Triglyceride and DOX+Talc+PCM control were demonstrated significant ( $p < 0.05$ ) level of Triglyceride when compared to DOX Control group (Table no. 1).

### Total Cholesterol (mg/dl)

The DOX control and Talc control were displayed significant ( $p < 0.001$ ) level of Total Cholesterol as compared to NC group while Talc control and DOX+Talc control, Talc+PCM control and DOX+Talc+PCM control were displayed significantly increased ( $p < 0.001$ ) level of Total Cholesterol as compared to DOX Control. DOX+PCM control were demonstrated not significant (*ns*) level of Total Cholesterol as compared to DOX Control (Table no. 2).

### Creatinine (mg/dl)

The DOX control and Talc control were displayed significantly upward ( $p < 0.001$ ) level of Creatinine as compared to NC group. Talc control and DOX+Talc control were showed not significant (*ns*) level of Creatinine as compared to DOX Control while PCM control, DOX+PCM control and Talc+PCM control were displayed significant ( $p < 0.001$ ) level of Creatinine as compared to DOX Control. In DOX+Talc+PCM control were demonstrated significantly decreased level ( $p < 0.05$ ) of Creatinine when compared to DOX Control (Table no. 1).

### HDL (mg/dl)

The DOX control and Talc control were displayed significantly downward ( $p < 0.001$ ) level of HDL as compared to NC group; while Talc control and DOX+Talc control were showed not significant (*ns*) level when compared with DOX control. In Talc+PCM control and DOX+Talc+PCM control were demonstrated significant level ( $p < 0.001$ ) level of HDL as related with DOX control (Table no. 2).

### LDL (mg/dl)

The DOX control were displayed significantly upward ( $p < 0.001$ ) level of LDL and Talc control were showed not significant (*ns*) level of LDL when compared with NC; on the other hand if Talc control and DOX+Talc control were compared with DOX control it showed not significant (*ns*) level of LDL. DOX+Talc+PCM control were demonstrated significant level ( $p < 0.001$ ) level of LDL as compared with DOX control (Table no. 2).

### Ca<sup>2+</sup> ion (m.eq/L)

The DOX control and Talc control were displayed significantly downward ( $p < 0.001$ ) level of Calcium ion as compared to NC group; while if Talc control, PCM control, DOX+Talc control and Talc+PCM control were showed not significant (*ns*) level of Calcium ion when compared to DOX Control. In DOX+Talc control and DOX+Talc+PCM control were demonstrated significantly increased level ( $p < 0.001$ ) of Calcium ion when compared to DOX Control (Table no. 2).

### Na<sup>+</sup> ion (m.eq/L)

The DOX control and Talc control were illustrated not significant (*ns*) level of Sodium ion as compared to NC group; while if Talc control, PCM control, DOX+Talc control, Talc+PCM control, DOX+Talc and DOX+Talc+PCM were also displayed not significant (*ns*) level of Sodium ion when compared to DOX Control (Table no. 2).

### K<sup>+</sup> ion (m.eq/L)

The DOX control were demonstrated not significant (*ns*) level and Talc control were displayed significantly upward ( $p < 0.001$ ) level of Potassium ion as compared to NC group; while if Talc control, DOX+Talc control and Talc+PCM control were compared to DOX Control it illustrated significantly increased ( $p < 0.001$ ) level of Potassium ion. In PCM control and DOX+PCM control were showed not significant (*ns*) level and DOX+Talc+PCM control were demonstrated significantly increased level ( $p < 0.05$ ) of Potassium ion when compared to DOX Control (Table no. 2).

### CPK-MB (U/L)

The DOX control Talc control were displayed significantly upward ( $p < 0.001$ ) level of CPK-MB as compared to NC group; while if Talc control, PCM control, DOX+Talc control, Talc+PCM control and

DOX+Talc+PCM were compared to DOX Control it illustrated significant ( $p<0.001$ ) level of CPK-MB. In and DOX+PCM control were demonstrated significantly decreased level ( $p<0.01$ ) of CPK-MB when compared to DOX Control (Table no. 1).

#### CRP (mg/L)

The DOX control and Talc control were displayed significantly increased ( $p<0.001$ ) level of CRP as compared to NC group; while if Talc control, DOX+Talc control were compared to DOX Control it illustrated not significant ( $ns$ ) level of CRP. PCM control and Talc+PCM control were significantly decreased ( $p<0.001$ ) level of CRP when compared to

DOX Control while In DOX+Talc+PCM control were demonstrated significantly diminished level ( $p<0.01$ ) of CRP when compared to DOX Control (Table no. 1).

#### Troponin-T (U/L)

The DOX control displayed significantly increased ( $p<0.05$ ) level of Troponin-T and Talc control were displayed significantly increased ( $p<0.001$ ) level of Troponin-Tas compared to NC group; while if Talc control, DOX+Talc control, Talc+PCM control and DOX+Talc+PCM control were compared to DOX Control it illustrated significantly elevated ( $p<0.001$ ) level of Troponin-T when compared to DOX Control (Table no. 1).

**Table 1: Data showing the effect of Talc on the levels of Blood glucose (mg/dl), Triglyceride (mg/dl), Creatinine (mg/dl), CRP (mg/L), Troponin-T (U/L), CPK-MB (U/L) of wistar rats**

S.N o.	Groups	Blood glucose (mg/dl)	Triglyceride (mg/dl)	Creatinine (mg/dl)	CRP (mg/L)	Troponin-T (U/L)	CPK-MB (U/L)
1	Normal control (NC)	73.83±3.43 9	47.67±2.41 8	0.620±0.040 4	1.733±0.066 6	0.533±0.019 6	65.83±4.72 9
2	DOX control	83.50±1.56 5 <sup>ns</sup>	56.33±1.83 8 <sup>ns</sup>	0.988±0.040 3 <sup>###</sup>	3.083±0.124 9 <sup>###</sup>	1.212±0.205 6 <sup>#</sup>	295.0±12.7 8 <sup>###</sup>
3	Talc control	240.7±4.63 1 <sup>***</sup>	122.7±2.98 5 <sup>***</sup>	0.978±0.057 7 <sup>ns</sup>	2.650±0.147 8 <sup>ns</sup>	4.700±0.171 3 <sup>***</sup>	614.7±3.57 5 <sup>***</sup>
4	PCM control	95.83±2.93 7 <sup>ns</sup>	61.83±1.81 5 <sup>ns</sup>	0.650±0.048 3 <sup>***</sup>	1.733±0.066 6 <sup>***</sup>	0.7667±0.09 71 <sup>ns</sup>	173.8±2.49 6 <sup>***</sup>
5	DOX +Talc control	213.3±9.97 2 <sup>***</sup>	60.83±2.28 6 <sup>ns</sup>	1.022±0.030 4 <sup>ns</sup>	2.850±0.133 5 <sup>ns</sup>	3.683±0.162 1 <sup>***</sup>	198.3±12.4 9 <sup>***</sup>
6	DOX +Met control	93.67±3.74 8 <sup>ns</sup>	69.00±2.74 5 <sup>*</sup>	0.681±0.009 4 <sup>***</sup>	2.517±0.135 2 <sup>*</sup>	1.075±0.162 4 <sup>ns</sup>	208.7±30.8 0 <sup>**</sup>
7	Talc+ PCM control	233.3±6.28 0 <sup>***</sup>	80.00±3.15 2 <sup>***</sup>	0.723±0.028 3 <sup>***</sup>	2.250±0.117 6 <sup>***</sup>	2.983±0.140 0 <sup>***</sup>	200.8±12.8 1 <sup>***</sup>
8	DOX+Talc+PCM control	225.0±3.65 1 <sup>***</sup>	68.33±1.02 2 <sup>*</sup>	0.815±0.016 6 <sup>*</sup>	2.367±0.143 0 <sup>**</sup>	2.283±0.113 8 <sup>***</sup>	129.0±7.23 4 <sup>***</sup>

Values are expressed as mean ± SEM (N= 6). (#) Groups as compared to normal control, (\*) Groups as compared to DOX control. *ns* –no significant; \*  $P<0.05$ ; \*\*  $P<0.01$ ; \*\*\*  $P<0.001$ .

**Table 2: Data showing the effect of Talc on the levels of Total Cholesterol (mg/dl), HDL (mg/dl), LDL (mg/dl),  $Ca^{2+}$ ion (m.eq/L),  $Na^{+}$ ion (m.eq/L),  $K^{+}$ ion (m.eq/L) of wistar rats**

S.N o.	Groups	Total Cholesterol (mg/dl)	HDL (mg/dl)	LDL (mg/dl)	$Ca^{2+}$ ion (m.eq/L)	$Na^{+}$ ion (m.eq/L)	$K^{+}$ ion (m.eq/L)
1	Normal control (NC)	72.00±3.642 9	21.67±0.881 9	45.0±1.713 9	9.233±0.06 66	151.0±0.730 3	4.050±0.076 3
2	DOX control	127.5±2.141 ###	12.83±0.600 9###	59.17±1.956 ###	8.10±0.243 ###	152.5±0.763 8 <sup>ns</sup>	4.383±0.186 9 <sup>ns</sup>
3	Talc control	110.8±3.070 *	14.33±1.022 <sup>n</sup> s	52.67±1.606 ns	7.667±0.15 6 <sup>ns</sup>	148.5±1.607 ns	6.383±0.233 ***
4	PCM control	71.50±1.875 ***	23.00±1.155* **	43.67±1.476 ***	7.633±0.08 8 <sup>ns</sup>	152.5±0.763 ns	4.683±0.074 9 <sup>ns</sup>

5	DOX +Talc control	105.8±2.301 **	11.67±0.557 8 <sup>ns</sup>	59.67±1.926 ns	9.100±0.10 65 <sup>***</sup>	150.7±0.666 ns	6.617±0.192 2 <sup>***</sup>
6	DOX +Met control	96.67±6.280 ***	18.17±0.792 3 <sup>**</sup>	47.50±2.487 ***	8.650±0.07 63 <sup>ns</sup>	151.3±1.145 ns	4.733±0.111 ns
7	Talc+ PCM control	93.17±2.12* **	23.33±0.881 9 <sup>***</sup>	48.33±1.726 **	7.750±0.12 5 <sup>ns</sup>	150.7±1.430 ns	6.467±0.154* **
8	DOX+Talc+P CM control	105.0±4.830 **	19.50±0.428 2 <sup>***</sup>	40.67±1.116 ***	9.050±0.04 28 <sup>***</sup>	152.8±0.945 ns	5.262±0.241* **

Values are expressed as mean ± SEM (N= 6). (#) Groups as compared to normal control, (\*) Groups as compared to DOX control. *ns* –no significant; \* *P*<0.05; \*\**P*<0.01; \*\*\**P*<0.001.

## Discussion

Cardiac remodelling is defined as genome expression, molecular, cellular, and interstitial changes that manifest clinically as changes in the size, shape, and function of the heart after cardiac injury [1] or increased cardiac load. Type 2 diabetes is associated with significantly higher risk of heart failure (HF), coronary artery disease (CAD) and cardiac remodelling [15]. The current American Heart Association, heart failure classification schema designates the presence of diabetes mellitus as stage A heart failure, which raises the risk of developing stage B heart failure or asymptomatic left ventricular (LV) dysfunction [16]. Individuals with diabetes frequently have LV remodelling; both increased LV mass and dilatation have been reported [17]; Researchers have also observed that factors associated with insulin resistance syndrome predate the development of LV systolic dysfunction by 2 decades, adjusting for ischemic heart disease and other risk factors [18]. Doxorubicin is an anti-tumour drug that is useful in treating several types of cancer, although its clinical use has been restricted due to cardiomyopathy induced by dose-dependent cardiotoxicity. Once cardiomyopathy occurs, treatment options are few, and doxorubicin-induced heart failure is usually refractory to conventional therapy. Hence, to evaluate Talc effect on doxorubicin-induced cardiomyopathy is the goal [19]. In the present study DOX control rats were not increased the level of glucose nor triglyceride, on the other hand Talc treated rats were demonstrated the significantly ( $p < 0.001$ ) high blood glucose level, altered insulin level, significant ( $p < 0.001$ ) higher circulating levels of triglycerides and lower high-density lipoprotein (HDL)-cholesterol concentrations and commonly manifest the metabolic syndrome [20]. The metabolic syndrome is a predictor of future risk of cardiovascular disease [21]. Specifically, it is widely recognized that higher levels of small dense low-density lipoprotein particles are a major contributor of increased risk for cardiovascular disease in insulin-resistant patients [22].

The association of different lipid fractions (especially the total cholesterol to HDL-cholesterol ratio) with incident heart failure is not the same as that for incident atherosclerotic cardiovascular events [23]. Evidence supports that higher triglyceride levels [24] or higher non-HDL-cholesterol levels [25] increase the risk of developing heart failure, perhaps because of the presence of insulin resistance that predisposes to metabolic changes characterized by impaired myocardial fatty acid oxidation and greater uncoupling of mitochondrial proteins in the heart [26]. Therefore in the Talc treated rats an insulin-resistant condition is developed which decreased uptake of myocardial glucose [27], resultant myocardial cells incapable to metabolize pyruvate, so that lipid accumulation in the myocardium is started [28]. However, the mechanisms by which free fatty acid metabolism and glucose oxidation are interrelated are quite complex [29]. Increased activation of different isomers of protein kinase C has been noted to play a role in inhibition of insulin secretion by free fatty acids [30]. On the other hand, hyperinsulinemia in diabetic patients is also associated with increased free fatty acid levels, elevated heart rate, and increased activation of sympathetic nervous system; all these factors subsequently lead to cardiac hypertrophy and intracellular accumulation of triglycerides. In the presence of hyperinsulinemia and insulin resistance, the heart has also been shown to reduce protein degradation, which may then promote myocardial hypertrophy [31]. In addition, dyslipidemia and production of free radicals result in alteration of genetic transcription factors and coding, which subsequently alters the translation of nucleoprotein genes such as those in the renin-angiotensin system (RAS) and IGF-1. Increased expression of RAS genes promotes insulin resistance, whereas greater expression of the IGF-1 gene increases sensitivity of cardiac myocytes to calcium concentrations and increases myocardial contractility. IGF-1 also acts synergistically

with angiotensin II in promoting cellular and myocardial hypertrophy [32]. Doxorubicin intoxication caused a significant increase ( $p < 0.001$ ) in the plasma concentration of Cholesterol, LDL and triglycerides and reduction in HDL; similar result was illustrated by Talc treated wistar rats. This indicates that doxorubicin and Talc may be interfering with metabolism or biosynthesis of lipids. Alterations in lipid metabolism and serum levels of cholesterol, triglyceride and LDL are some of the biochemical indices that are often used in the prediction of cardiovascular disease risk [33]. Diabetes mellitus is frequently associated with impaired lipid metabolism such as elevated cholesterol and triglycerides (TG) and abnormalities in serum lipoproteins [34]. Talc treated rats showed elevation of blood glucose level leads disturbance in triglyceride level of blood which further interfere with cholesterol, lipid metabolism, lowered HDL and increased LDL level; that could generate cardiac dysfunction in Wistar rats and by the time may induces cardiac remodelling like condition. A high level of LDL can be suggestive of medical problems such as diseases of cardiovascular system, also the higher the level, the higher the risk for coronary artery disease in Talc treated rats [35, 36]. Lipids play an important role in the pathogenesis of myocardial ischemia. Hypercholesterolemia and hypertriglyceridemia are the risk factor for the development of myocardial ischemia. Increased levels of blood cholesterol and their accumulations in the heart are well associated with myocardial damage [37]. Creatinine is filtered out of the blood by the kidney and is a direct measure of renal excretory function. If the filtering by the kidney is deficient, plasma levels rises above normal, the urine levels reduces. Serum creatinine concentration increases when more than 50% of renal function has been lost [38]. Although creatinine, like urea, is not generally considered to be an important uremic toxin, both compounds have been shown experimentally to be toxic in acutely uremic rats [39]. It is however a known fact that kidney function is compromised in uncontrolled diabetes mellitus. Glycosuria, which is a pertinent diagnostic feature of diabetes, causes dehydration via glucose osmotic diuresis. This dehydration is accompanied with severe loss of electrolytes including sodium, potassium, calcium, chloride and phosphates. A decrease in concentration of plasma sodium (hyponatremia) could be suggestive of diseases of the liver, kidney or congestive heart failure [40]. Persistent low levels of sodium in plasma in diabetic rats here is unacceptable because of the increased risk of developing congestive heart failure. In the present study plasma sodium level were slightly decreased in Talc control, but on comparison with

normal control and DOX control it were not significant (*ns*). Potassium depletion inhibits insulin secretion and is associated with glucose intolerance, whereas potassium infusion and hyperkalemia increase the secretory rate of insulin by changing the membrane potential of pancreatic beta cells [41]. In the current protocol Talc control showed the significant increased level of plasma Potassium level which indicated that Talc treated Wistar rats trying to maintain the insulin level by changing potential of beta cells. In addition,  $Ca^{2+}$  handling alterations in vascular smooth muscle cell (VSMCs) contribute to blood vessel dysfunction associated with diabetes. VSMCs provide not only structural integrity to the vessels but also actively regulate arterial tone and local blood pressure via diverse  $Ca^{2+}$  signalling pathways [42]. Vascular dysfunction is a distinctive phenotype found in both types of diabetes and likely contributes to the high incidence of stroke and heart attack, not to mention organ damage, such as retinopathy and nephropathy, that is observed in diabetic patients [43, 44]. The CK system of isoenzymes consists of CK-MM, CK-MB, CK-BB, and mitochondrial-CK. Each subunit of the dimeric CK is regulated by a distinct gene, and expressed in a tissue-specific manner. In humans and animals, CK-MB is found predominately in the myocardium; with concentration ranges from 5 to 30% of the total CK activity of the heart. The largest portion of the heart is composed of CK-MM. CK-MB, a golden standard marker of myocyte injury or death, leaks out from myocardium due to disintegration of the contractile apparatus and increased sarcoplasmic permeability. When ischemia destructs cell membrane, these enzymes are leaked out of cells [45]; so the level shows the injury rate and cell necrosis [46]. In Talc control and DOX control significantly ( $p < 0.001$ ) elevated level of CK-MB clearly said that Talc may responsible for the myocardial cell injury or membrane integrity in current research. C-reactive protein (CRP) as a sensitive marker of inflammation has been widely studied, its level regulated primarily by the function of cytokines, such as interleukin-6 (IL-6). It binds to a wide variety of substances, such as microbial polysaccharide, phosphatidylcholine, and damaged cell membrane. CRP also enhances the activity of phagocytic cells and activates the classical complement pathway [47]. The differences seen in CRP concentrations between the normal control, DOX control and Talc controls remained highly significant after the adjustment for hypertension, diabetes. These increases in CRP levels also reflect the severity of coronary disease [48]. Our data of the elevated CRP levels in the wistar rats with increased levels of LDL may raise the possibility of the cardiac disorder.

Cardiac troponin is regulatory proteins that control the calcium mediated interaction of actin and myosin resulting in contraction and relaxation of striated muscle. Greaser et al. demonstrated that the troponin complex comprised three distinct proteins: troponin C (TnC), for binding  $Ca^{2+}$  and regulating thin filament activation; troponin I (TnI), for inhibiting actin-activated myosin ATPase activity; and troponin T (TnT), for binding tropomyosin (Tm) [49]. Troponin I and T are two proteins of the thin filament regulatory system of the contractile complex of heart and skeletal muscle. TnI is encoded by three different genes that are differentially expressed by various muscle tissues. Cardiac troponin I (cTnI) is uniquely specific for the heart, containing a 31-amino acid sequence on its N-terminus that differentiates it from the fast and slow skeletal forms. Troponin T is also expressed by three different genes, resulting in slow and fast skeletal isoforms and a cardiac (cTnT) form [50, 51]. Cardiac troponin T is an established biochemical marker of myocyte damage which can be used to assess myocyte damage from myocardial infarction [52]. Increased TnT in the circulation translates to heart injury. Troponin predicts the occurrence of clinically significant LV dysfunction at least 3 months in advance [53, 54]. The observation that Troponin T concentrations are significantly increased ( $p < 0.001$ ) in the DOX and Talc treated wistar rats, which clearly indicated that may some injury happened in myocardial wall, previous researcher gave us various case study that supported protocol results. Cardiac troponin plays a crucial role in the diagnosis of myocardial necrosis. According to the universally accepted definition, myocardial infarction is diagnosed when blood levels of sensitive and specific biomarkers such as cTn or CK-MB are increased in the clinical setting of acute myocardial ischemia [55-56]. Although cTnT and cTnI increase in blood reflect injury leading to necrosis of myocardial cells, they do not provide any clues with respect to the underlying disease mechanism. Various possibilities have been suggested for the release of structural proteins from the myocardium, including normal turnover of myocardial cells, apoptosis, cellular release of troponin degradation products, increased cellular wall permeability, formation, and release of membranous blebs and myocyte necrosis.

### Conclusion

In the conclusion, it can be said that due to increased plasma glucose and Triglyceride level in the blood, insulin resistance may occur; it may alter the lipid metabolism which generated the ROS production in heart wall and deposited fatty acid in blood vessels wall this may change the blood flow; therefore blood pressure is increased and activation of rennin angiotensin system occur, may deposition of fatty acid damage the blood vessel wall. By altering Troponin T, CRP; Talc may stimulate the vascular inflammation by various circulating

proinflammatory cytokines such as interleukin-6, interleukin 1-beta. These cytokines are responsible to generate the NOS expression and nitrite production which produce ROS formation and subsequent MAPK development may lead to oxidation of myofilaments and induced cardio-myocyte apoptosis; furthermore this may promote the diabetes cardiomyopathy and if this condition retain for long time it will lead to cardiac remodeling, but through intensive research is required for our understanding of the role of Talc as a promoter of cardiac remodeling, it represents attractive but challenging targets for the future.

### References

1. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling- concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling, *Journal of American College Cardiology* 2000;35(3):569-582.
2. Dorn GW 2nd, Robbins J, Sugden PH. Phenotyping hypertrophy: eschew publication, *Circulation Research* 2003; 92:1171.
3. Gansevoort RT. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention, *Lancet* 2013;382(9889): 339-52.
4. Tomas S, Matin S, Olga P, Michaela A, Radomir H, Vladimir G. Anthracycline- Induced cardiotoxicity Overview of studies examining the roles of oxidative Stress and free cellular iron, *Pharmacology Report* 2009; 61: 154-171
5. <http://pubchem.ncbi.nlm.nih.gov/compound/doxorubicin#section=Top>. (08 January 2013 )
6. Hardman JG, Limbird LE, Goodman GA. Goodman's the pharmacological basis of therapeutics. McGraw-Hill Book Company, New York 2001:112-115.
7. Payasi A, Chaudhary M, Singh BM, Gupta A, Sehgal R. Sub-acute toxicity studies of Paracetamol infusion in albino Wistar rats, *International Journal for Scientific Research & Development* 2010: 2.
8. Gross P, De Treville RTP, Cralley LJ, Harley RA. Asbestos-Induced intrathoracic tissue reactions, *Archives of Pathology*, 1973; 96:245.
9. Golightly LK, Smolinske SS, Bennett ML, Sutherland EW, III Rumack BH. Pharmaceutical excipients. Adverse effects associated with "inactive" ingredients in drug products (Part II), *Medical Toxicology Anti Adverse Drug Experience* 1988;3: 209.
10. Singh Rajbala, Muhammad Afzal, Imran Kazmi, Firoz Anwar. Talc used in anticancer drugs is promoter for diabetes in hepatocellular carcinoma induced rats, *European Journal of Cancer* 2014; 50: 247– 248.

11. Tang WH. Glycemic control and treatment patterns in patients with heart failure, *Current Cardiology Reports* 2007;9:242-247.
12. Stratton IM, Adler AI, Neil HA. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (United Kingdom Prospective Diabetes Study 35): prospective observational study, *British Medical Journal* 2000;321:405-412.
13. Gottdiener JS, Arnold AM, Aurigemma GP. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study, *Journal of American College Cardiology*, 2000;35:1628-1637.
14. Follath F. University Hospital Zurich, Switzerland: ESC Congress 2007 Press Release: September 2, 2007.
15. Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on health-care costs: results from the UK prospective diabetes study (UKPDS Study no. 65), *Diabetes Medicine* 2003;20:442-50.
16. Schocken DD, Benjamin EJ, Fonarow GC. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. *Circulation* 2008;117: 2544-65.
17. Lindman BR, Arnold SV, Madrazo JA. The adverse impact of diabetes mellitus on left ventricular remodeling and function in patients with severe aortic stenosis, *Circulation Heart Failure* 2011;4(3): 286-92.
18. Arnlov J, Lind L, Zethelius BR. Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of followup, *American Heart Journal* 2001;142: 720-4.
19. Hirose K, Shu NH, Reed JE, Rumberger JA. Right ventricular dilatation and remodeling the first year after an initial transmural wall left ventricular myocardial infarction, *American Journal Cardiology* 1993;72:1126-30.
20. Grundy SM, Cleeman JI, Daniels SR. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific statement, *Circulation* 2005;112(17):2735-52.
21. Wilson PW, D'Agostino RB, Parise H. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus, *Circulation* 2005;112:3066-72.
22. Kathiresan S, Otvos JD, Sullivan LM. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study, *Circulation* 2006;113:20-9.
23. Dhingra R, Sesso HD, Kenchaiah S. Differential effects of lipids on the risk of heart failure and coronary heart disease: the Physicians' Health Study, *American Heart Journal* 2008;155:869-75.
24. Pillutla P, Hwang YC, Augustus A. Perfusion of hearts with triglyceride-rich particles reproduces the metabolic abnormalities in lipotoxic cardiomyopathy, *American Journal of Physiology Endocrinology Metabolism* 2005;288: E1229-35.
25. Velagaleti RS, Massaro J, Vasan RS. Relations of lipid concentrations to heart failure incidence: the Framingham Heart Study, *Circulation* 2009; 120:2345-51.
26. Murray AJ, Anderson RE, Watson GC. Uncoupling proteins in human heart, *Lancet* 2004;364:1786-8.
27. Dutka DP, Pitt M, Pagano D. Myocardial glucose transport and utilization in patients with type 2 diabetes mellitus, left ventricular dysfunction, and coronary artery disease, *Journal of American College Cardiology* 2006;48:2225-31.
28. Taegtmeier H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: part I: general concepts, *Circulation* 2002;105:1727-33.
29. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. *Circulation* 2007;115:3213-23.
30. Itani SI, Zhou Q, Pories WJ. Involvement of protein kinase C in human skeletal muscle insulin resistance and obesity, *Diabetes* 2000;49:1353-8.
31. McNulty PH, Louard RJ, Deckelbaum LI. Hyperinsulinemia inhibits myocardial protein degradation in patients with cardiovascular disease and insulin resistance, *Circulation* 1995;92:2151-6.
32. Ren J, Samson WK, Sowers JR. Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. *Journal of Molecular Cell Cardiology* 1999; 31: 2049-61.
33. Dhingra R, Sesso HD, Kenchaiah S. Differential effects of lipids on the risk of heart failure and coronary heart disease: the Physicians' Health Study, *American Heart Journal* 2008;155:869-75.
34. Cromwell WL, Otvos JD. Low density lipoprotein particles number and risk for cardiovascular disease, *Current Atherosclerosis Report* 2004; 6: 381-387.
35. Erejuwa OO, Sulaiman SA, AbWahab MS. Honey - a novel antidiabetic agent, *International Journal of Biological Science* 2012; 8: 913-34.
36. Segrest JP, Li L, Anantharmaiah GM, Harvey SC, Liadaki KN, Zamis V. Structure and function of apolipoprotein A-I and high density lipoprotein. *Current Opinion Lipidology* 2000; 11:105-115.



37. EL-Hilaly J, Tahraoui A, Israili ZH, Lyoussi B. Hypolipidemic effects of acute and sub chronic administration of an aqueous extract of *Ajuga reptans* whole plant in normal and diabetic rats, *Journal of Ethnopharmacology* 2006; 105(3):441-446.
38. Salter AM, White DA. Effects of dietary fat on cholesterol metabolism; regulation of plasma LDL concentration, *Nutrition Research Review* 1996;9:241-257.
39. Yager HM, Harrington JT. Evaluation of serum electrolytes, creatinine and blood urea nitrogen. In: Jacobson HR, Striker GE, Klahr S (Editors), *Principles and practice of nephrology*. 2nd edn. St. Louis: Mosby; 1995: 85-89.
40. Levine S, Saltzman A. Are urea and creatinine uremic toxins in the rat? *Renal Failure* 2001; 23: 53-59.
41. Markel H and David Murray MD. When it rains it pours: endemic goiter, iodized salt. *American journal of public health* 1987; 77 (2): 219-229.
42. Rowe JW, Tobin JD, Rosa RM, Andres R. Effect of experimental potassium deficiency on glucose and insulin metabolism, *Metabolism* 1980; 29:498-502.
43. Marchand A, Abi-Gerges Y, Saliba E, Merlet A, Lompré M. Calcium signaling in vascular smooth muscle cells: from physiology to pathology, *Advance Experiment Medical Biology* 2012; 740: 795-810.
44. Tabit CE, Chung WB, Hamburg NM, Vita JA. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications, *Review of Endocrinology Metabolic Disorder* 2010; 11: 61-74.
45. Eringa EC, Serne EH, Meijer RI, Schalkwijk CG, Houben AJ, Stehouwer CD, Smulders YM, van Hinsbergh VW. Endothelial dysfunction in (pre)diabetes: characteristics, causative mechanisms and pathogenic role in type 2 diabetes, *Review of Endocrinology Metabolic Disorder* 2013; 14: 39-48.
46. Downey JM, Cohen MV. Free radicals in the heart: Friend or foe? *Expert Review Cardiovascular Theory* 2008;6:589-91.
47. Rossoni G, Manfredi B, Civelli M, Berti F, Razzetti R. Combined simvastatin-manidipine protect against ischemia-reperfusion injury in isolated hearts from normocholesterolemic rats, *European Journal of Pharmacology* 2008;587:224-30.
48. Davey Smith G, Lawlor DA, Harbord R. Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality, *Arteriosclerosis Thrombosis Vascular Biology* 2005;25:1051-6.
49. Onat A, Can G, Hergenc G. Serum C-reactive protein is an independent risk factor predicting cardiometabolic risk, *Metabolism* 2008;57:207-14.
50. Parmacek MS, Solaro RJ. Biology of the troponin complex in cardiac myocytes, *Prog. Cardiovascular Diseases* 2004; 47: 159-176.
51. Wu AHB. In: *Cardiac markers*, 1st ed, Humana Press, Totowa, NJ: 1998.
52. Kaski JC, Holt DW. In: *Myocardial damage: early detection by novel biochemical markers*, Kluwer Academic Publishers, London: 1998.
53. Wu AHB, Valdes Jr. R, Apple FS. Cardiac troponin T immunoassay for diagnosis of acute myocardial infarction. *Clinical Chemistry* 1994;40:900-7.
54. Cardinale D, Sandri MT, Martinoni A. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy, *Oncology* 2002; 13: 710-715.
55. Kilickap S, Barista I, Akgul E. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity, *Annals of Oncology* 2005; 16: 798-804.
56. Thygesen K, Alpert JS, White HD, Universal definition of myocardial infarction, *Journal of American College Cardiology* 2007; 50: 2173-2195

**Source of Support:** Nil

**Conflict of Interest:** None